Athira Pharma Inc

NASDAQ:ATHAUnited States

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and stop neurodegeneration. The Company's lead candidate, fosgonimeton (ATH-1017), is a subcutaneously administered, blood brain barrier (BBB)-penetrating, small molecule HGF/MET positive modulator. The primary target indication is Alzheimers disease. The ATH-1017, is a subcutaneous administered, BBB-penetrating, small molecule hepatocyte growth factor/mesenchymal-epithelial transition factor (HGF/MET) activator for the treatment of neurodegenerative disorders, with an initial focus on Alzheimer's disease (AD). It also has preclinical candidates for non-AD indications, including ATH-1018, which is being developed to address peripheral indications, and ATH-1019/ATH-1020 compounds, which are being advanced to address neuropsychiatric indications. ATH technology is designed to promote HGF/MET activity for a variety of clinical applications.

Contact Information

Headquarters

18706 North Creek Parkway Suite 104, Box 352141BOTHELL, WA, United States 98011

Phone

425-620-8501

Fax

302-636-5454

Executives

Independent Chairwoman of the Board

Kelly Romano

President, Chief Executive Officer, Director

Mark Litton

Chief Financial Officer

Glenna Mileson

Chief Operating Officer

Rachel Lenington

Executive Vice President - Research

Kevin Church